Eli Lilly's eloralintide achieves 20% weight loss in obesity study

cnbc.com

Eli Lilly's experimental amylin drug, eloralintide, achieved up to 20% weight loss in a mid-stage study. The weekly injection will advance to late-stage trials next month, with the highest dose showing an average 20.1% body weight reduction over 48 weeks. Amylin analogs are seen as the next wave of obesity treatments, potentially complementing or offering an alternative to existing GLP-1 drugs.


With a significance score of 4.7, this news ranks in the top 1.8% of today's 29976 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Eli Lilly's eloralintide achieves 20% weight loss in obesity study | News Minimalist